Miralax Safety for Chronic Constipation

This article is general health information, not medical advice and not original research. It summarizes published studies and guidelines. Always talk with your own physician before starting, stopping, or continuing any medication for you or your child.

As a pediatrician, I talk with families about constipation almost every day. It is one of the most common problems I see, and it affects mood, appetite, energy, and quality of life. When diet, fluids, and routine changes are not enough, Miralax often enters the conversation, and so does a very fair question from parents: “Is it safe?”

There is a lot of conflicting information online, including real concerns raised by parent groups. I want to walk through what the published evidence actually shows, including where questions remain, so you can have an informed conversation with your doctor.

What Miralax Is and How It Works

Miralax is the brand name for polyethylene glycol 3350, or PEG 3350. It belongs to a class of medications called osmotic laxatives.

Unlike stimulant laxatives (such as senna or bisacodyl), which trigger the colon to contract, PEG 3350 works like a sponge. It holds onto water as it moves through the digestive tract. That extra water softens the stool and makes it easier to pass, working with the body rather than forcing it.

What the Research Shows About Absorption

A key part of the safety discussion is absorption. Published pharmacology data show that PEG 3350 is minimally absorbed from the digestive tract in healthy people. Most of the dose passes through the gut and leaves the body in the stool. Because very little reaches the bloodstream, it has a low risk of interacting with medications for blood pressure, diabetes, or heart conditions.

To be precise: minimally absorbed does not mean zero absorption. Small amounts of PEG and related compounds can be detected in the body, and researchers continue to study absorption in children, whose bodies differ from adults. That ongoing research is discussed in the children’s section below.

What Clinical Trials Show About Effectiveness

PEG 3350 has been tested in randomized, placebo controlled trials. In one double blind trial in adults with chronic constipation, patients taking PEG 3350 with electrolytes averaged about 4.3 spontaneous bowel movements per week, compared with about 1.6 per week in the placebo group, and the improvement held up through a 52 week extension study (Mishima et al., Journal of Gastroenterology, 2019). In pediatric trials, PEG significantly increased weekly stool frequency compared with placebo, with adverse effects similar to placebo (summary of pediatric PEG trials).

Guidelines from the North American and European societies for pediatric gastroenterology (NASPGHAN and ESPGHAN) recommend PEG as a first line treatment for functional constipation in children, under the supervision of a physician. In the societies’ updated 2026 guideline, PEG is the only constipation treatment to receive a strong recommendation (see References 2 and 3).

The “Antifreeze” Question

Many parents have read that Miralax is related to antifreeze. Here is the accurate version: PEG 3350 and ethylene glycol (the toxic chemical in antifreeze) are chemically related compounds, but they are not the same substance and do not behave the same way in the body. It is similar to how rubbing alcohol and drinking alcohol are chemically related but very different. Miralax does not contain antifreeze. Trace impurities in manufacturing are regulated and monitored by the FDA.

Miralax and Children: An Honest Look at the Controversy

This deserves its own section, because it is where most parent concern lives, and the concern is understandable.

Here are the facts as they stand today:

• Miralax is not FDA approved for children under 17. When pediatricians recommend it for younger children, that is off label use. Off label prescribing is legal and common in pediatrics, because many medications were never formally studied for FDA approval in children, but parents deserve to know this.

• Families have reported adverse events. The FDA has received reports from parents describing behavioral and neuropsychiatric symptoms in children taking PEG 3350. These reports are why the FDA funded research at Children’s Hospital of Philadelphia to study PEG 3350 in children.

• Research to date has not established a causal link. The FDA has stated there is insufficient evidence to demonstrate a connection between PEG 3350 and serious neuropsychiatric events in children, and the major pediatric gastroenterology societies continue to recommend it as first line therapy. Reported events have not been shown to occur more often in children taking PEG than in children who are not.

• Untreated chronic constipation carries its own real harms, including pain, stool withholding, fissures, and encopresis. Pediatric gastroenterologists weigh those harms against the unresolved questions when they recommend treatment.

My approach in practice: I start with diet, hydration, and behavioral measures. When medication is needed, I discuss the evidence and the open questions with parents, we use the lowest effective dose, and we monitor together. If a child develops any concerning symptom, we reassess. No parent should feel dismissed for asking questions about this medication, and no child should suffer with untreated constipation out of fear.

Comparing Laxative Types

Long Term Use

Chronic constipation often needs a maintenance plan, not a one time fix. PEG 3350 is not habit forming in the way stimulant laxatives can be, and published trials have followed patients on daily use for up to a year without a pattern of serious adverse effects (Mishima et al., 2019). Long term use should still always happen under a doctor’s supervision, both to confirm the dose and to rule out underlying causes such as thyroid problems or, in children, conditions like Hirschsprung disease.

The goal of maintenance therapy is to keep stool soft enough to pass without straining, which protects against hemorrhoids, fissures, and stool withholding cycles in children.

Use in Pregnancy and in Older Adults

Constipation is very common in pregnancy. Because PEG 3350 is minimally absorbed, it is often considered a preferred option for pregnant patients, in consultation with their OB. For older adults on multiple medications, its low potential for drug interactions makes it a frequent choice as well.

How to Use It Correctly

When patients tell me Miralax “did not work,” the cause is usually dosing, timing, or hydration.

• Dissolve it fully in 4 to 8 ounces of water, juice, or another beverage. Temperature does not affect how it works.

• Drink fluids through the day. The medication works by holding water, so it needs water available.

• Give it time. It typically takes 1 to 3 days to produce a bowel movement. Taking extra doses early will not speed it up and can cause diarrhea later.

• For children, dosing is weight based and should come from your pediatrician, not the adult label. Do not adjust a child’s dose on your own.

• Be consistent. For chronic constipation, a steady daily routine usually works better than occasional large doses.

When to Call Your Doctor

Stop self treating and call your doctor if you or your child has severe abdominal pain, blood in the stool, vomiting, unexplained weight loss, or no relief after two weeks of use. In children, also call if constipation began in the first month of life, or if there is fever, a swollen abdomen, or refusal to eat. These can signal a condition that needs a different workup.

For trusted general information on constipation, see the National Institute of Diabetes and Digestive and Kidney Diseases.

The Bottom Line

Based on the published evidence and current guidelines, PEG 3350 is considered safe and effective for most patients when used as directed under medical supervision, including for longer term management of chronic constipation. For children, it remains the first line medication recommended by pediatric gastroenterology societies, while research continues and while every family deserves a straightforward conversation about off label status and reported concerns. If you are unsure, ask. That conversation is exactly what we are here for.